Log in to your Inderes Free account to see all free content on this page.
Bavarian Nordic
201.00 DKK
+0.50 %
Less than 1K followers
BAVA
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Bavarian Nordic
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 662.5 | 1,852.4 | 1,897.9 | 3,150.8 | 7,062.3 | 5,716.2 | 6,244.0 |
| growth-% | 179.6 % | 2.5 % | 66.0 % | 124.1 % | -19.1 % | 9.2 % | |
| EBITDA | -271.4 | 739.7 | 74.8 | 328.5 | 2,614.0 | 1,603.1 | 2,541.9 |
| EBIT | -328.4 | 379.6 | -313.5 | -70.8 | 1,502.5 | 939.8 | 1,803.8 |
| Profit before taxes | -344.7 | 282.0 | -454.4 | -331.6 | 1,482.9 | 971.4 | 1,801.0 |
| Net income | -346.8 | 277.5 | -464.8 | -347.4 | 1,475.2 | 988.0 | 1,375.4 |
| EPS | -8.73 | 5.10 | -7.97 | -4.90 | 19.20 | 12.60 | 17.60 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | 0.0 % | -0.0 % | -0.0 % | 0.0 % | 0.0 % | 0.0 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -41.0 % | 39.9 % | 3.9 % | 10.4 % | 37.0 % | 28.0 % | 40.7 % |
| EBIT-% | -49.6 % | 20.5 % | -16.5 % | -2.2 % | 21.3 % | 16.4 % | 28.9 % |
| ROE | -18.6 % | 5.7 % | -6.3 % | -4.9 % | 14.3 % | 8.7 % | 10.7 % |
| ROI | -4.9 % | 3.2 % | -3.8 % | -2.8 % | 10.3 % | 6.9 % | 9.2 % |
Login required
This content is only available for logged in users